308 related articles for article (PubMed ID: 35053220)
1. Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer.
You CP; Leung MH; Tsang WC; Khoo US; Tsoi H
Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053220
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW; Lee KS
Ann Oncol; 2011 Aug; 22(8):1755-62. PubMed ID: 21310761
[TBL] [Abstract][Full Text] [Related]
3. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.
Kono M; Fujii T; Lim B; Karuturi MS; Tripathy D; Ueno NT
JAMA Oncol; 2017 Sep; 3(9):1266-1273. PubMed ID: 28301631
[TBL] [Abstract][Full Text] [Related]
4. The role of the androgen receptor in triple-negative breast cancer.
Shah PD; Gucalp A; Traina TA
Womens Health (Lond); 2013 Jul; 9(4):351-60. PubMed ID: 23826776
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
[TBL] [Abstract][Full Text] [Related]
6. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor signaling pathways as a target for breast cancer treatment.
Pietri E; Conteduca V; Andreis D; Massa I; Melegari E; Sarti S; Cecconetto L; Schirone A; Bravaccini S; Serra P; Fedeli A; Maltoni R; Amadori D; De Giorgi U; Rocca A
Endocr Relat Cancer; 2016 Oct; 23(10):R485-98. PubMed ID: 27528625
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Importance of Androgen Receptor Status in Response to Neoadjuvant Chemotherapy in Turkish Patients with Local and Locally Advanced Breast Cancer.
Arici S; Sengiz Erhan S; Geredeli C; Cekin R; Sakin A; Cihan S
Oncol Res Treat; 2020; 43(9):435-440. PubMed ID: 32570261
[TBL] [Abstract][Full Text] [Related]
9. Expression of androgen receptors in primary breast cancer.
Park S; Koo J; Park HS; Kim JH; Choi SY; Lee JH; Park BW; Lee KS
Ann Oncol; 2010 Mar; 21(3):488-492. PubMed ID: 19887463
[TBL] [Abstract][Full Text] [Related]
10. Distribution and characteristics of androgen receptor (AR) in breast cancer among women in Addis Ababa, Ethiopia: A cross sectional study.
Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Karlsson C; Karlsson MG
PLoS One; 2020; 15(5):e0232519. PubMed ID: 32374753
[TBL] [Abstract][Full Text] [Related]
11. Expression of androgen receptor and its phosphorylated forms in breast cancer progression.
Ren Q; Zhang L; Ruoff R; Ha S; Wang J; Jain S; Reuter V; Gerald W; Giri DD; Melamed J; Garabedian MJ; Lee P; Logan SK
Cancer; 2013 Jul; 119(14):2532-40. PubMed ID: 23605249
[TBL] [Abstract][Full Text] [Related]
12. Role of the androgen receptor in triple-negative breast cancer.
Rampurwala M; Wisinski KB; O'Regan R
Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
[TBL] [Abstract][Full Text] [Related]
13. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status.
Jiang HS; Kuang XY; Sun WL; Xu Y; Zheng YZ; Liu YR; Lang GT; Qiao F; Hu X; Shao ZM
Oncotarget; 2016 Jul; 7(27):41285-41293. PubMed ID: 27285752
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
[TBL] [Abstract][Full Text] [Related]
16. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
Tang D; Xu S; Zhang Q; Zhao W
Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
18. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
Liu D
Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
[TBL] [Abstract][Full Text] [Related]
19. The Role of the Androgen Receptor Signaling in Breast Malignancies.
Christopoulos PF; Vlachogiannis NI; Vogkou CT; Koutsilieris M
Anticancer Res; 2017 Dec; 37(12):6533-6540. PubMed ID: 29187427
[TBL] [Abstract][Full Text] [Related]
20. Quadruple-negative breast cancer: novel implications for a new disease.
Bhattarai S; Saini G; Gogineni K; Aneja R
Breast Cancer Res; 2020 Nov; 22(1):127. PubMed ID: 33213491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]